Michael Thomas Henderson net worth and biography

Michael Henderson Biography and Net Worth

Michael Henderson, M.D., joined Apogee in September 2022 and serves as Chief Executive Officer and Board member. He is a proven biotechnology industry leader with expertise in business leadership, drug development, and commercial strategy. He also serves on the Board of Spyre Therapeutics. Prior to joining Apogee, Dr. Henderson spearheaded the creation of more than 20 companies, launched 40 drug development programs, and led two teams to FDA approvals. Dr. Henderson received his B.A. from Harvard University and holds an M.D. from Stanford University. Originally from Oklahoma, he is a die-hard fan of the Oklahoma Sooners and a sworn enemy of any football team that opposes them.

What is Michael Thomas Henderson's net worth?: The estimated net worth of Michael Thomas Henderson is at least $73.79 million as of October 2nd, 2024. Dr. Henderson owns 1,354,487 shares of Apogee Therapeutics stock worth more than $73,792,452 as of October 4th. This net worth evaluation does not reflect any other investments that Dr. Henderson may own. Additionally, Dr. Henderson receives an annual salary of $1,170,000.00 as CEO at Apogee Therapeutics. Learn More about Michael Thomas Henderson's net worth.
How old is Michael Thomas Henderson?: Dr. Henderson is currently 34 years old. There are 4 older executives and no younger executives at Apogee Therapeutics. Learn More on Michael Thomas Henderson's age.
What is Michael Thomas Henderson's salary?: As the CEO of Apogee Therapeutics, Inc., Dr. Henderson earns $1,170,000.00 per year. Learn More on Michael Thomas Henderson's salary.
How do I contact Michael Thomas Henderson?: The corporate mailing address for Dr. Henderson and other Apogee Therapeutics executives is 221 Crescent Street, Building 17 Suite 102b, Waltham, MA 02453, United States. Apogee Therapeutics can also be reached via phone at 650-394-5230 and via email at [email protected]. Learn More on Michael Thomas Henderson's contact information.
Has Michael Thomas Henderson been buying or selling shares of Apogee Therapeutics?: In the last ninety days, Michael Thomas Henderson has sold $2,249,200.00 of Apogee Therapeutics stock. Most recently, Michael Thomas Henderson sold 40,000 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $56.23, for a transaction totalling $2,249,200.00. Following the completion of the sale, the chief executive officer now directly owns 1,354,487 shares of the company's stock, valued at $76,162,804.01. Learn More on Michael Thomas Henderson's trading history.
Who are Apogee Therapeutics' active insiders?: Apogee Therapeutics' insider roster includes Jane Henderson (CFO), and Michael Henderson (CEO). Learn More on Apogee Therapeutics' active insiders.
Are insiders buying or selling shares of Apogee Therapeutics?: In the last year, insiders at the sold shares 9 times. They sold a total of 167,660 shares worth more than $7,842,946.75. The most recent insider tranaction occured on October, 2nd when insider Carl Dambkowski sold 6,665 shares worth more than $374,972.90. Insiders at Apogee Therapeutics own 36.1% of the company. Learn More about insider trades at Apogee Therapeutics.
Information on this page was last updated on 10/2/2024.

Michael Thomas Henderson Insider Trading History at Apogee Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/2/2024	Sell	40,000	$56.23	$2,249,200.00	1,354,487
9/4/2024	Sell	40,000	$47.62	$1,904,800.00	1,394,487
8/7/2024	Sell	40,000	$40.62	$1,624,800.00	1,434,487
7/5/2024	Sell	15,000	$37.26	$558,900.00	1,474,487

Michael Thomas Henderson Buying and Selling Activity at Apogee Therapeutics

Apogee Therapeutics Company Overview

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $54.48

$54.04

$57.93

50 Day Range

MA: $49.58

$40.36

$59.92

2 Week Range

Now: $54.48

$14.19

$72.29

Volume

325,606 shs

Average Volume

512,581 shs

Market Capitalization

$3.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.74

Gold at $2,600... But This Stock Gives You More for Under $20

From Monument Traders Alliance | Ad

Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an ounce of gold... for less than $20?

Click here now to learn how you can position yourself for potentially massive gains.

Michael Henderson Biography and Net Worth

What is Michael Thomas Henderson's net worth?

How old is Michael Thomas Henderson?

What is Michael Thomas Henderson's salary?

How do I contact Michael Thomas Henderson?

Has Michael Thomas Henderson been buying or selling shares of Apogee Therapeutics?

Who are Apogee Therapeutics' active insiders?

Are insiders buying or selling shares of Apogee Therapeutics?